Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02515240 · ClinicalTrials.gov registry record · Early Phase 1
Immune Response to Pneumococcal Vaccination in HIV Infected Individuals
A Early Phase 1 study, sponsored by University of Toledo Health Science Campus.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 124
- Enrollment target
NCT02515240: Completed Early Phase 1 study, sponsored by University of Toledo Health Science Campus.
NCT02515240 is a Early Phase 1 study that has completed, run by University of Toledo Health Science Campus. The registered enrollment target is 124 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (134% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02515240, a Early Phase 1 study, has completed, sponsored by University of Toledo Health Science Campus.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of the study. To characterize the immune response to the pneumococcal vaccine in HIV positive individuals and to dissect the most appropriate timing and frequency of vaccination.
Interventions
- BIOLOGICAL PPV23
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-03 |
| Phase | Early Phase 1 |
What the finished NCT02515240 record still lists
NCT02515240 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (134% higher).
The record links to 0 conditions, and to 1 intervention - of which PPV23 is the first listed.
NCT02515240 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02515240 about?
NCT02515240 is a clinical study titled "Immune Response to Pneumococcal Vaccination in HIV Infected Individuals". The purpose of the study. To characterize the immune response to the pneumococcal vaccine in HIV positive individuals and to dissect the most appropriate timing and frequency of vaccination.
What is the current status of trial NCT02515240?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 124 participants. The study started on 2010-07. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02515240?
The interventions under investigation include: PPV23 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02515240?
This trial is sponsored by University of Toledo Health Science Campus, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02515240's enrollment target sits among peer trials
124 145th of 2000 higher than 1,854 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia